Bristol-Myers Squibb (BMY) Tops Q3 EPS by 6c

Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $2.00, $0.06 better than the analyst estimate of $1.94. Revenue for the quarter came in at $11.62 billion versus the consensus estimate of $11.64 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2021 EPS of $7.40-$7.55, versus the consensus of $7.47.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Build-A-Bear Workshop (BBW) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY Guidance
• Ulta Beauty (ULTA) Tops Q2 EPS by 38c, Offers Outlook